The characteristics of the 5-HT2A receptor antagonist sarpogrelate and the PDE III inhibitor cilostazol on heart rate, electrocardiogram and blood pressure in peripheral circulatory disorders

H. Iwakuma, R. Suenaga, K. Hachimine, S. Kuga, H. Ishii, K. Hiraoka, S. Ito, Nobuhiro Nakamoto

Research output: Contribution to journalArticle

Abstract

The incidence of peripheral occlusive diseases increase from year to year. Through the individual treatment, the management of heart rate, myocardial damage and blood pressure, including influential factors to peripheral flow, and the prevention of progressive circulatory disorders are important. In this study, 78 patients with peripheral occlusive diseases were investigated based on influences of these factors before and after administration of sarpogrelate and cilostazol as antiplatelet agents. Sarpogrelate was insignificant except the shortening in QTc in prolonged QTc. Cilostazol had the increase in heart rate, the prolongation in QTc in normal QTc and the reduction of diastolic blood pressure in cases along with increase in heart rate. Above mentioned results may be explained from their different concentration of intracellular Ca that influences on the slope of diastolic depolarization in pacemaker cells (heart rate) and the plateau of action potential in myocardial cells (QTc). Sarpogrelate as a 5HT2 receptor antagonist and cilostazol as a PDE III inhibitor promotes a decrease and an increase in intracellular Ca, repectively. The restoration of myocardial damage and the unchanged heart rate and blood pressure using sarpogrelate can be useful in elderly patients, and expected to prevent the serious conditions. Cilostazol may be better in point of the insufficiency of peripheral flow as a result of bradycardia.

Original languageEnglish
Pages (from-to)365-370
Number of pages6
JournalTherapeutic Research
Volume22
Issue number2
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Serotonin 5-HT2 Receptor Antagonists
Receptor, Serotonin, 5-HT2A
Electrocardiography
Heart Rate
Blood Pressure
Platelet Aggregation Inhibitors
Bradycardia
Action Potentials
sarpogrelate
cilostazol
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The characteristics of the 5-HT2A receptor antagonist sarpogrelate and the PDE III inhibitor cilostazol on heart rate, electrocardiogram and blood pressure in peripheral circulatory disorders. / Iwakuma, H.; Suenaga, R.; Hachimine, K.; Kuga, S.; Ishii, H.; Hiraoka, K.; Ito, S.; Nakamoto, Nobuhiro.

In: Therapeutic Research, Vol. 22, No. 2, 2001, p. 365-370.

Research output: Contribution to journalArticle

@article{e9ca5c9c17de464b874afbf91dfb0fba,
title = "The characteristics of the 5-HT2A receptor antagonist sarpogrelate and the PDE III inhibitor cilostazol on heart rate, electrocardiogram and blood pressure in peripheral circulatory disorders",
abstract = "The incidence of peripheral occlusive diseases increase from year to year. Through the individual treatment, the management of heart rate, myocardial damage and blood pressure, including influential factors to peripheral flow, and the prevention of progressive circulatory disorders are important. In this study, 78 patients with peripheral occlusive diseases were investigated based on influences of these factors before and after administration of sarpogrelate and cilostazol as antiplatelet agents. Sarpogrelate was insignificant except the shortening in QTc in prolonged QTc. Cilostazol had the increase in heart rate, the prolongation in QTc in normal QTc and the reduction of diastolic blood pressure in cases along with increase in heart rate. Above mentioned results may be explained from their different concentration of intracellular Ca that influences on the slope of diastolic depolarization in pacemaker cells (heart rate) and the plateau of action potential in myocardial cells (QTc). Sarpogrelate as a 5HT2 receptor antagonist and cilostazol as a PDE III inhibitor promotes a decrease and an increase in intracellular Ca, repectively. The restoration of myocardial damage and the unchanged heart rate and blood pressure using sarpogrelate can be useful in elderly patients, and expected to prevent the serious conditions. Cilostazol may be better in point of the insufficiency of peripheral flow as a result of bradycardia.",
author = "H. Iwakuma and R. Suenaga and K. Hachimine and S. Kuga and H. Ishii and K. Hiraoka and S. Ito and Nobuhiro Nakamoto",
year = "2001",
language = "English",
volume = "22",
pages = "365--370",
journal = "Therapeutic Research",
issn = "0289-8020",
publisher = "Life Science Publishing Co. Ltd",
number = "2",

}

TY - JOUR

T1 - The characteristics of the 5-HT2A receptor antagonist sarpogrelate and the PDE III inhibitor cilostazol on heart rate, electrocardiogram and blood pressure in peripheral circulatory disorders

AU - Iwakuma, H.

AU - Suenaga, R.

AU - Hachimine, K.

AU - Kuga, S.

AU - Ishii, H.

AU - Hiraoka, K.

AU - Ito, S.

AU - Nakamoto, Nobuhiro

PY - 2001

Y1 - 2001

N2 - The incidence of peripheral occlusive diseases increase from year to year. Through the individual treatment, the management of heart rate, myocardial damage and blood pressure, including influential factors to peripheral flow, and the prevention of progressive circulatory disorders are important. In this study, 78 patients with peripheral occlusive diseases were investigated based on influences of these factors before and after administration of sarpogrelate and cilostazol as antiplatelet agents. Sarpogrelate was insignificant except the shortening in QTc in prolonged QTc. Cilostazol had the increase in heart rate, the prolongation in QTc in normal QTc and the reduction of diastolic blood pressure in cases along with increase in heart rate. Above mentioned results may be explained from their different concentration of intracellular Ca that influences on the slope of diastolic depolarization in pacemaker cells (heart rate) and the plateau of action potential in myocardial cells (QTc). Sarpogrelate as a 5HT2 receptor antagonist and cilostazol as a PDE III inhibitor promotes a decrease and an increase in intracellular Ca, repectively. The restoration of myocardial damage and the unchanged heart rate and blood pressure using sarpogrelate can be useful in elderly patients, and expected to prevent the serious conditions. Cilostazol may be better in point of the insufficiency of peripheral flow as a result of bradycardia.

AB - The incidence of peripheral occlusive diseases increase from year to year. Through the individual treatment, the management of heart rate, myocardial damage and blood pressure, including influential factors to peripheral flow, and the prevention of progressive circulatory disorders are important. In this study, 78 patients with peripheral occlusive diseases were investigated based on influences of these factors before and after administration of sarpogrelate and cilostazol as antiplatelet agents. Sarpogrelate was insignificant except the shortening in QTc in prolonged QTc. Cilostazol had the increase in heart rate, the prolongation in QTc in normal QTc and the reduction of diastolic blood pressure in cases along with increase in heart rate. Above mentioned results may be explained from their different concentration of intracellular Ca that influences on the slope of diastolic depolarization in pacemaker cells (heart rate) and the plateau of action potential in myocardial cells (QTc). Sarpogrelate as a 5HT2 receptor antagonist and cilostazol as a PDE III inhibitor promotes a decrease and an increase in intracellular Ca, repectively. The restoration of myocardial damage and the unchanged heart rate and blood pressure using sarpogrelate can be useful in elderly patients, and expected to prevent the serious conditions. Cilostazol may be better in point of the insufficiency of peripheral flow as a result of bradycardia.

UR - http://www.scopus.com/inward/record.url?scp=0035032223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035032223&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035032223

VL - 22

SP - 365

EP - 370

JO - Therapeutic Research

JF - Therapeutic Research

SN - 0289-8020

IS - 2

ER -